TENX
Tenax TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
TENX now has a defined registrational setup: LEVEL hit its randomization target, topline data are expected in Q3 2026, and LEVEL-2 has begun, creating a credible pathway to a material re-rate if efficacy replicates prior promise in PH-HFpEF [#8-K-2026-03-10].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +4.4.
What can break
Capital raise or partnership terms become the dominant narrative before pivotal data arrive.
Momentum
15
Value
41
Sentiment
59
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $12.00 · Bull $18.00 · Bear $7.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $25.25
Why
Momentum15 · Δ7d -0.9
Value41 · Δ7d +0.1
Sentiment59 · Δ7d +4.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
15
34% active weight
Current posture
7d trendFlat
Δ7d
-0.9
Δ21d
+1.5
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
59
33% active weight
Current posture
7d trendImproving
Δ7d
+4.4
Δ21d
+7.6
Why this grade
Composite grade F. Momentum 15.1 / Value 41.1 / Sentiment 58.5
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$290.45M
Beta
1.41
Shares Out
6.24M
P/E (TTM) · Derived
-40.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-68.28
Rev YoY
-
EPS YoY
-112.5%
Gross Margin
-
Op Margin
-
Net Debt
-$94.85M
Current Ratio
15.58
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology